BliNK Biomedical provides a B‑cell technology platform that directly screens and isolates individual antibody‑producing cells from human and other animal sources, using its proprietary ISAAC and VIVA|Screen systems. The high‑throughput, deep‑mining approach can detect extremely rare antibody‑secreting cells across multiple species, enabling the generation of unique therapeutic antibody candidates that are difficult to obtain with conventional methods.
Funding
Funding not disclosed
Founders
Product
Problem
Discovering therapeutic antibodies against challenging targets is limited by the difficulty of identifying and isolating the extremely rare B cells that produce them, especially when working across multiple species.
Solution
BliNK Biomedical offers a B‑cell technology platform that directly screens and isolates individual antibody‑producing cells from human and other animal sources. The approach leverages the validated ISAAC and VIVA|Screen systems to perform deep, high‑efficiency mining of B‑cell repertoires, enabling the detection of very low‑frequency antibody‑secreting cells. By capturing these rare cells, the platform generates unique antibody candidates that are difficult to obtain with conventional hybridoma or phage‑display methods. The isolated antibodies can then be further developed into therapeutic candidates for a range of disease areas.
Target Audience
Primary customers are pharmaceutical and biotechnology companies, as well as academic research groups, that require advanced antibody discovery for difficult or novel targets.
Features
- High‑throughput single‑cell selection and isolation of antibody‑producing B cells
- Compatibility with B cells from multiple species (human, mouse, rabbit, dog, etc.)
- Deep mining capability to detect extremely rare antibody‑secreting cells
- Utilizes proprietary ISAAC and VIVA|Screen platforms for efficient screening
- Generates unique therapeutic antibody candidates not accessible by standard methods